Clinical Trials
25 trialsNCT00726232 2025-10-29
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Incyte Corporation
Phase 2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04551066 2025-10-21
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
Phase 3 Terminated
NCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT03755518 2024-12-12
FREEDOM
Celgene
Phase 3 Terminated
NCT04637009 2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT02718300 2024-05-01
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
Phase 2 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT04631211 2023-05-25
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
Phase 2 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT04866056 2022-12-01
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Terminated
NCT02587598 2021-12-08
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03287245 2021-12-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
Phase 2 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT03123588 2021-11-19
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
Phase 2 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT00020969 2020-10-05
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Phase 2 Terminated
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT01066468 2012-03-13
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Novartis
Phase 1 Terminated
NCT00522574 2011-04-05
A Safety Study of XL019 in Adults With Myelofibrosis
Exelixis
Phase 1 Terminated